Statement: SkinBioTherapeutics Announcement

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes provides a statement relating to the recent announcements made by SkinBioTherapeutics ("SBTX").

OptiBiotix recognises the uncertainty in the market from recent announcements by SBTX and its impact on the value of the Company's 5.64% holding in SBTX. OptiBiotix confirms it has no current intention to sell its SBTX shares. The Company confirms it has not sold any ProBiotix Health ("PBX") shares and has no current plans to sell PBX shares.

The Company's unaudited cash position as of 31st December 2025 was just over £1 million (2024: £739k) with no current requirement to raise new funds. The Company's focus is on increasing sales, improving margins, and reducing costs to develop a sustainable business, and launching its second-generation products. Considerable progress has already been made in growing sales, particularly of high margin product lines, with orders for 2026 previously reported of over £800K (announced: 21 January 2026). The Company has developed profit and loss accounts for each part of its business (OptiBiotix Health USA, OptiBiotix Health India, Ecommerce and B2B) with each business unit tasked with covering its direct costs by the end of 2026. Considerable progress has also been made in January 2026 in managing marketing spend in Ecommerce with its Amazon account now profitable and its China Ecommerce account anticipated to be profitable in forthcoming months.

Stephen O'Hara, CEO of OptiBiotix, commented:

"The board recognises the uncertainty recent announcements by SBTX have had on the value of its holding in SBTX and indirectly in OPTI itself. The Company believes the fundamentals of its business are strong and reminds investors of material progress in its SweetBiotix products (announced: 24 November 2025) and a recent large order from Meelung of 24mt (announced: 21 January 2026) and record start to 2026. The Board believes it is in the strongest position it has been in with its first-generation products and making strong progress with its second-generation products."

Engage with the OptiBiotix management team directly by asking questions, watching video summaries and seeing what other shareholders have to say by subscribing to the new website to get regular updates: https://optibiotix.com/auth/signup

View the full announcement and submit questions to management via our website: https://optibiotix.com/link/PmpRXr

Caution regarding forward looking statements